Rutgers University Research Center and Janssen Develop Continuous Manufacturing Process - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rutgers University Research Center and Janssen Develop Continuous Manufacturing Process


ePT--the Electronic Newsletter of Pharmaceutical Technology

Researchers in the Engineering Research Center for Structured Organic Particulate Systems (C-SOPS) at Rutgers, the State University of New Jersey, have collaborated with Janssen to develop a direct-compaction line using continuous manufacturing principles. C-SOPS researchers built a full-scale production line at the Rutgers to test concepts and define a design space. Janssen is now constructing a line based on that design, which is targeted for completion in 2014.

C-SOPS, based on the Rutgers University campus and in partnership with Purdue University, The New Jersey Institue of Technology, and The University of Puerto Rico at Mayagüez, brings together a cross-disciplinary group of engineers, scientists, and industry leaders from academia, pharmaceutical manufacturers, and equipment manufacturers. C-SOPS has been investigating continuous manufacturing concepts since 2006 and has worked on both the fundamental science and commercialization of advanced pharmaceutical manufacturing. The continuous direct compaction line replaces the traditional multi-stage batch process by integrating feeders, mills, blenders, and a tablet press into a single continuous process.

In developing the line, C-SOPS researchers defined parameters and performed design space experiments to evaluate the effect of parameter changes. “Because the process is continuous, we were able to measure parameter-change effects in nearly real time; we performed a full set of design experiments with dozens of conditions, in hours rather than days to weeks, and used a fraction of the API needed for batch processing,” explains Douglas Hausner, associate director for industrial relations and business development at C-SOPS.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here